Probmet

Probmet is a precision oncology therapeutics company that is developing targeted treatments for breast cancer brain metastatic patients. Every year 1.7 million women are diagnosed with primary breast cancer. In almost 700,000 people it will spread beyond the breast to other parts of the body including the brain, lungs, liver and bone. There is a lack of effective targeted therapies available to these patients.

The current management strategy for patients with metastases are incremental changes of existing therapies that were designed for the primary tumour and not specifically for the metastatic tumours. In addition, in many cases the tumours have developed resistance to currently available therapies and therefore a different approach to uncover new therapeutic targets for these patients is needed.

Brain metastases is particularly difficult to treat due to the blood-brain barrier preventing substances being delivered to the central nervous system.

Probmet Therapeutics has developed a peptide mimetic against the neuropeptide LGI1 to target the receptor ADAM22 as a targeted therapeutic and biomarker selection strategy to treat breast cancer brain metastasis.

ProbMet graphicPromoters

Current status

  • Currently incubated at the BioInnovation Institute in Copenhagen
  • The company is non-diluted with €700,000 in convertible note from BioInnovation Institute and grants
  • The company holds exclusive rights on patents granted in EU and US

Next steps

  • The company is currently raising €4.5m to advance their lead compound towards clinical stage in breast cancer brain metastasis that offers regulatory and market advantages.
Spin-out summary – Probmet PDF | 682.5 KB